Resistance profiles in surgical-site infection

Future Microbiology

Volumn 3, Issue 4, 2008, Pages 453-462

  Lenz, Andreas M ^a   Fairweather, Mark ^a   Cheadle, William G ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Antimicrobials; Infection; Resistance; Staphylococcus aureus; Surgery

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOXITIN; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DALBAVANCIN; DAPTOMYCIN; ICLAPRIM; LINEZOLID; METICILLIN; METRONIDAZOLE; ORITAVANCIN; PANTON VALENTINE LEUKOCIDIN; PROTEIN MEC TYPE IV; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CHROMOSOME; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM CONTAMINATION; BACTERIUM ISOLATE; FATALITY; GENE CASSETTE; GENETIC CODE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INSTRUMENT STERILIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROTECTIVE CLOTHING; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; SKIN DECONTAMINATION; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; SURGICAL WOUND;

COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MODELS, BIOLOGICAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 48649085575     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.4.453     Document Type: Review

References (84)

1. Altemeier WA: Sepsis in surgery. Presidential address. Arch. Surg. 117(2), 107-112 (1982).
2. Polk HC Jr, Lopez-Mayor JF: Postoperative wound infection: a prospective study of determinant factors and prevention. Surgery (66(1), 97-103 (1969).
3. Cheadle WG: Risk factors for surgical site infection. Surg. Infect. (Larchmt) 7(Suppl. 1), S7-S11 (2006).
4. Barle PS: Surgical site infections: epidemiology and prevention. Surg. Infect. (Larchmt) 3(Suppl. 1), S9-S21 (2002).
5. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR: Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect. Control Hosp. Epidemiol. 20(4), 250-278 (1999).
6. Barnett TE: The not-so-hidden costs of surgical site infections. AORN J. 86(2), 249-258 (2007).
7. Klevens RM, Edwards JR, Richards CL Jr et al.: Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 122(2), 160-166 (2007).
8. Sessler DI: Non-pharmacologic prevention of surgical wound infection. Anesthesiol. Clin. 24(2), 279-297 (2006).
9. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ: The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect. Control Hosp. Epidemiol. 20 (11), 725-730 (1999).
10. Leaper DJ, van Goor H, Reilly J et al.: Surgical site infection: a European perspective of incidence and economic burden. Int. Wound. J. 1 (4), 247-273 (2004).
11. Engemann J.J, Carmeli Y, Cosgrove SE et al.: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococrus aureus surgical site infection. Clin. Infect. Dis. 36(5), 592-598 (2003).
12. Cohen ML: Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257(5073), 1050-1055 (1992).
13. DiNubile MJ, Lipsky BA: Complicated infections of skin and skin structures: when the infection is more than skin deep. J. Antimicrob. Chemother. 53(Suppl. 2), ii37-ii50 (2004).
14. DiNubile MJ, Lipsky BA: Surgical site infections. Surg. Clin. N. Am. 85(6), 1115-1135, viii-ix (2005).
15. Turina M, Cheadle WG: Clinical challenges and unmet needs in the management of complicated skin and skin structure, and soft tissue infections. Surg. Infect. (Larchmt) 6 (Suppl. 2), 23-36 (2005).
16. Malone DL, Genuit T, Tracy JK, Gannon C, Napolitano LM: Surgical site infections: reanalysis of risk factors. J. Surg. Res. 103(1), 89-95 (2002).
17. Gaynes R, Edwards JR: Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41(6), 848-854 (2005).
18. National Nosocomial Infections Surveillance (NNIS) System Report: data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32(8), 470-485 (2004).
19. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS: Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant Staphlylococcus aureus. Infect. Control Hosp. Epidemiol. 28(9), 1047-1053 (2007).
20. No authors listed. A NEW penicillin. Br. Med. J. 2 (5200), 720-721 (1960).
21. No authors listed. 'Celbemom'-resistant staphylococci. Br. Med. J. 1(5219), 113-114 (1961).
22. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R: Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin. Infect. Dis. 42(3), 389-391 (2006).
23. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta analysis. Clin. Infect. Dis. 36(1), 53-59 (2003).
24. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y: The impact of methicillin resistance in Staphylacoccus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26(2), 166-174 (2005).
25. Klevens RM, Morrison MA, Nadle J et al.: Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15), 1763-1771 (2007).
26. Yetman L: A new 'superbug' leaves the hospital: community-acquired methicillin-resistant Staphylococcus aureus. Home Healthc. Nurse 24(4), 213-216 (2006).
27. Graffunder EM, Venezia RA: Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J. Antimicrob. Chemother. 49(6), 999-1005 (2002).
28. Monnet DL: Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect. Control Hosp. Epidemiol. 19(8), 552-559 (1998).
29. Marshall C, Kossmann T, Wesselingh S, Spelman D: Methicillin-resistant Staphylococcus aureus and beyond: what's new in the world of the golden staph? ANZ J. Surg. 74(6), 465-469 (2004).
30. Garnier F. Tristan A, Francois B et al.: Pneumonia and new methicillin-resistant Staphylococcus aureus clone. Emerg. Infect Dis. 12(3), 498-500 (2006).
31. Davis SL, Rybak MJ, Amjad M, Kaatz GW, McKinnon PS: Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphlylococcus aureus. Infect. Control Hosp. Epidemiol. 27(10), 1025-1031 (2006).
32. Patel M, Hoesley CJ, Moser SA, Stamm AM, Baddley JW, Waites KB: Dissemination of community-associated methicillin-resistant Staphylococcus aureus in a tertiary care hospital. South. Med. J. 101 (1), 40-45 (2008).
33. Otter JA, French GL: The emergence of community-associated methicillin-resistant Staphylococcus aureus at a London teaching hospital, 2000-2006. Clin. Microbiol. Infect. 14(7), 670-676 (2008).
34. Gonzalez BE, Rueda AM, Shelburne SA 3rd, Musher DM, Hamill RJ, Hulten KG: Community associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect. Control Hosp. Epidemiol. 27(10), 1051-1056 (2006).
35. Kourbatova EV, Halvosa JS, King MD, Ray SM, White N, Blumberg HM: Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am. J. Infect. Control 33(7), 385-391 (2005).
36. Seybold U, Kourbatova EV, Johnson JG et al.: Emergence of community associated methicillin-resistant Staphylococcus aureus USA 300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42(5), 647-656 (2006).
37. Patel M, Kumar RA, Stamm AM, Hoesley CJ, Moser SA, Waites KB: USA300 genotype community-associated methicillin-resistant Staphylococcus aureus as a cause of surgical site infections. J. Clin. Microbiol. 45(10), 3431-3433 (2007).
38. Naimi TS, LeDell KH, Como-Sabetti K et al.: Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290(22), 2976-2984 (2003).
39. Bocchini CE, Hulten KG, Mason EO Jr, Gonzalez BE, Hammerman WA, Kaplan SL: Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children Pediatrics 117(2), 433-440 (2006).
40. Lee YT, Lin JC, Wang NC, Peng MY, Chang FY: Necrotizing fasciitis in a medical center in northern Taiwan: emergence of methicillin-resistant Staphylococcus aureus in the community. J. Microbiol. Immunol. Infect. 40(4), 335-341 (2007).
41. Young LM, Price CS: Community-acquired methicillin-resistant Staphylococcus aureus emerging as important cause of necrotizing fasciitis. Surg. Infect. (Larchmt) (2008) (Epub ahead of print).
42. Tristan A, Ferry T, Durand G et al.: Virulence determinants in community and hospital meticillin-resistant Staphylococcus aureus. J. Hosp. Infect. 65(Suppl. 2). 105-109 (2007).
43. Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl. 1), S35-S39 (2006).
44. Appelbaum PC: Microbiology of antibiotic resistance in Staphylococcus aureus. Clin. Infect. Dis. 45(Suppl. 3), S165-S170 (2007).
45. Appelbaum PC: Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 30(5), 398-408 (2007).
46. Tenover FC, McDonald LC: Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr. Opin. Infect. Dis. 18(4), 300-305 (2005).
47. Whitener CJ, Park SY, Browne FA et al.: Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin. Infect. Dis. 38(8), 1049-1055 (2004).
48. Perichon B, Courvalin P: Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 48(11), 4281-4285 (2004).
49. Weigel LM, Clewell DB, Gill SR et al.: Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302(5650), 1569-1571 (2003).
50. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother 49(6), 2260-2266 (2005).
51. Weigelt J, Kaafarani HM, Itani KM, Swanson RN: Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg. 188(6), 760-766 (2004).
52. Itani KM, Weigelt J, Li JZ, Duttagupta S: Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents 26(6), 442-448 (2005).
53. Hentschke M, Saager B, Horstkotte MA et al.: Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection 36(1), 85-87 (2007).
54. Enoch DA, Bygott JM, Daly ML, Karas JA: Daptomycin. J. Infect. 55(3), 205-213 (2007).
55. Hair PI, Keam SJ: Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 67(10), 1483-1512 (2007).
56. Micek ST: Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3), S184-S190 (2007).
57. von Eiff C, Arciola CR, Montanaro L, Becker K, Campoccia D: Emerging Staphylococcus species as new pathogens in implant infections. Int. J. Artif. Organs 29(4), 360-367 (2006).
58. Vadyvaloo V, Otto M: Molecular genetics of Staphylococcus epidermidis biofilms on indwelling medical devices. Int. J. Artif. Organs 28(11), 1069-1079 (2005).
59. Tegnell A, Aren C, Ohman L: Coagulase-negative staphylococci and sternal infections after cardiac operation. Ann. Thorac. Surg. 69(4), 1104-1109 (2000).
60. Gardlund B, Bitkover CY, Vaage J: Postoperative mediastinitis in cardiac surgery: microbiology and pathogenesis. Eur. J. Cardiothorac. Surg. 21(5), 825-830 (2002).
61. Mah TF, O'Toole GA: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9(1), 34-39 (2001).
62. Stefani S, Varaldo PE: Epidemiology of methicillin-resistant staphylococci in Europe. Clin. Microbiol. Infect. 9(12), 1179-1186 (2003).
63. Vuong C, Otto M: Staphylococcus epidermidis infections. Microbes. Infect. 4(4), 481-489 (2002).
64. Marothi YA, Agnihotri H, Dubey D: Enterococcal resistance: an overview. Indian J. Med. Microbiol. 23(4), 214-219 (2005).
65. Martone WJ: Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect. Control Hosp. Epidemiol. 19(8), 539-545 (1998).
66. Murray BE: Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342(10), 710-721 (2000).
67. Leclercq R, Derlot E, Duval J, Courvalin P: Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319(3), 157-161 (1988).
68. Uttley AH, Collins CH, Naidoo J, George RC: Vancomycin-resistant enterococci. Lancet 1(8575-8576), 57-58 (1988).
69. Sahm DF, Kissinger J, Gilmore MS et al.: In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Cbemother. 33(9), 1588-1591 (1989).
70. Karlowsky JA, Jones ME, Draghi DC, Thornsberry C, Sahm DF, Volturo GA: Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann. Clin. Microbiol. Antimicrob. 3, 7 (2004).
71. Rice LB: Antimicrobial resistance in Gram-positive bacteria. Am. J. Infect. Control 34(5 Suppl. 1), S11-S19 (2006).
72. Garey KW, Lai D, Dao-Tran TK, Gentry LO, Hwang LY, Davis BR: Interrupted time series analysis of vancomycin compared to cefuroxime for surgical prophylaxis in patients undergoing cardiac surgery. Antimicrob. Agents Chemother. 52(2), 446-451 (2008).
73. Garey KW, Dao T, Chen H et al.: Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. J. Antimicrob. Chemother. 58(3), 645-650 (2006).
74. Kachroo S, Dao T, Zabaneh F et al.: Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant enterococcus colonization. Ann. Pharmacother. 40(3), 381-385 (2006).
75. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J: Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis. 31(1), 101-106 (2000).
76. Abraham EP, Chain E: An enzyme from bacteria able to destroy penicillin. 1940. Rev. Infect. Dis. 10(4), 677-678 (1988).
77. Nicasio AM, Kuti JL, Nicolau DP: The current state of multidrug-resistant Gram-negative bacilli in North America. Pharmacotherapy 28(2), 235-249 (2008).
78. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S: Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxine in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 11(6), 315-317 (1983).
79. Paterson DL, Bonomo RA: Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657-686 (2005).
80. Bush K: Extended-spectrum β-lactamases in North America, 1987-2006. Clin. Microbiol. Infect. 14(Suppl. 1), 134-143 (2008).
81. Canton R, Novais A, Valverde A et al.: Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 14(Suppl. 1), 144-153 (2008).
82. Franklin GA, Moore KB, Snyder JW, Polk HC Jr, Cheadle WG: Emergence of resistant microbes in critical care units is transient, despite an unrestricted formulary and multiple antibiotic trials. Surg. Infect. (Larchmt) 3(2), 135-144 (2002).
83. Paterson DL, Rice LB: Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin. Infect. Dis. 36(8), 1006-1012 (2003).
84. Wexler HM: Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20(4), 593-621 (2007).